Axitinib/Axitinib medical insurance reimbursement conditions updated in 2025: Which patients meet the criteria

Axitinib is a kinase inhibitor primarily used to treat advanced renal cell carcinoma (RCC). With the update of the medical insurance policy in 2025, the reimbursement conditions and scope of application of axitinib have also been adjusted accordingly, providing patients with more treatment options. The medical insurance reimbursement conditions for axitinib are mainly determined based on the patient’s condition, treatment history, and stage of drug use.

According to the latest medical insurance policy, axitinib, as a second-line treatment drug, is suitable for patients with advanced renal cell carcinoma who have received one systemic treatment but had poor efficacy. Specifically, axitinib may be reimbursed as a follow-up treatment option for patients whose disease has progressed or is resistant to conventional therapy. Such patients usually receive treatment options including tyrosine kinase inhibitors (TKI) or immune checkpoint inhibitors in the early stage of treatment.

In addition, axitinib can be used in combination with other drugs as a first-line treatment option in some patients. The latest medical insurance policy allows the combination of axitinib and avelumab (Avelumab) for the treatment of advanced renal cell carcinoma, applicable to patients who have not received any treatment. Through combination therapy, the patient's survival period has been significantly extended, which has also made the application of axitinib in first-line treatment recognized by medical insurance.

Combined use with immunotherapy is also an application method of axitinib, especially in patients who have poor response to traditional treatments. Combination treatment of axitinib andpembrolizumab has been proven to significantly improve the efficacy. According to the update of the medical insurance policy, eligible patients can also obtain this treatment plan within the scope of medical insurance.

The 2025 medical insurance policy has optimized the reimbursement conditions for axitinib. Patients can enjoy medical insurance reimbursement benefits according to their own treatment needs if they meet the conditions. However, specific reimbursement conditions may vary by region and hospital. Patients should fully communicate with the attending doctor before treatment and confirm whether the required treatment meets the requirements of the medical insurance policy.

Reference materials:https://en.wikipedia.org/wiki/Axitinib